BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36252550)

  • 1. Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer.
    Okamoto K; Nozawa H; Emoto S; Murono K; Sasaki K; Ishihara S
    Oncology; 2022; 100(11):576-582. PubMed ID: 36252550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study.
    Osawa H; Handa N; Minakata K
    Oncol Res; 2014; 22(5-6):325-31. PubMed ID: 26629945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.
    Okamoto K; Nozawa H; Emoto S; Murono K; Sasaki K; Ishihara S
    Support Care Cancer; 2023 Oct; 31(12):660. PubMed ID: 37897532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
    Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
    BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer.
    Nozawa H; Kawai K; Sasaki K; Murono K; Emoto S; Yokoyama Y; Abe S; Kishikawa J; Nagai Y; Sonoda H; Anzai H; Ozawa T; Ishihara S
    Int J Clin Pract; 2021 Nov; 75(11):e14863. PubMed ID: 34516723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
    Satake H; Hashida H; Tanioka H; Miyake Y; Yoshioka S; Watanabe T; Matsuura M; Kyogoku T; Inukai M; Kotake T; Okita Y; Matsumoto T; Yasui H; Kotaka M; Kato T; Kaihara S; Tsuji A
    Oncologist; 2021 Jul; 26(7):e1125-e1132. PubMed ID: 33977607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
    Iveson TJ; Kerr RS; Saunders MP; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Scudder C; Boyd KA; Briggs A; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan HS; Paul J
    Lancet Oncol; 2018 Apr; 19(4):562-578. PubMed ID: 29611518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection.
    Xu JL; Tang CW; Feng WM; Bao Y; Chai ZZ
    Med Sci Monit; 2019 Jun; 25():4831-4836. PubMed ID: 31254462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
    Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R
    BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.
    van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt JF; Maas HA; Lemmens VE
    Int J Cancer; 2017 Jan; 140(1):224-233. PubMed ID: 27615021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool.
    Lin JK; Tan EC; Yang MC
    Health Qual Life Outcomes; 2015 May; 13():61. PubMed ID: 25986478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study.
    Yamazaki K; Matsumoto S; Imamura CK; Yamagiwa C; Shimizu A; Yoshino T
    Jpn J Clin Oncol; 2020 Feb; 50(2):122-128. PubMed ID: 31665356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients.
    van Erning FN; Razenberg LG; Lemmens VE; Creemers GJ; Pruijt JF; Maas HA; Janssen-Heijnen ML
    Eur J Cancer; 2016 Jul; 61():1-10. PubMed ID: 27128782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
    Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT
    Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.
    Loree JM; Sha A; Soleimani M; Kennecke HF; Ho MY; Cheung WY; Mulder KE; Abadi S; Spratlin JL; Gill S
    Clin Colorectal Cancer; 2018 Jun; 17(2):156-163. PubMed ID: 29486916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis.
    Breadner D; Loree JM; Cheung WY; Gipson M; Lakkunarajah S; Mulder KE; Spartlin JL; Kong S; Ding PQ; Gill S; Welch SA
    BMC Cancer; 2022 Nov; 22(1):1119. PubMed ID: 36319973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study.
    Sha A; Abadi S; Gill S
    J Oncol Pharm Pract; 2018 Oct; 24(7):501-506. PubMed ID: 28714378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy for elderly patients with colorectal cancer: a single-centre observational study in Japan.
    Okamoto K; Nozawa H; Emoto S; Murono K; Sasaki K; Ishihara S
    J Chemother; 2024 Jul; 36(4):319-328. PubMed ID: 37881011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.